Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients

Pharmacokinetic-based prophylaxis of replacement factor VIII (FVIII) products has been encouraged in recent years, but the relationship between exposure (factor VIII activity) and response (bleeding frequency) remains unclear. The aim of this study was to characterize the relationship between FVIII...

Full description

Bibliographic Details
Published in:	Haematologica
Main Authors:	João A. Abrantes, Alexander Solms, Dirk Garmann, Elisabet I. Nielsen, Siv Jönsson, Mats O. Karlsson
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2020-05-01
Online Access:	https://haematologica.org/article/view/9399

Similar Items

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
by: Laura H. Bukkems, et al.
Published: (2023-05-01)

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
by: Jules Russick, et al.
Published: (2020-04-01)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
by: Andreas Tiede, et al.
Published: (2020-04-01)

P1626: A SINGLE-CENTER EXPERIENCE IN INCREASING FACTOR VIII LEVELS TO ACHIEVE ZERO BLEEDING IN PATIENTS WITH SEVERE HEMOPHILIA A.
by: Rubén Clavero López, et al.
Published: (2023-08-01)

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine
by: Caesar Mahmoud Abu Arra, et al.
Published: (2020-01-01)

Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A
by: Diego Zanolini, et al.
Published: (2015-07-01)

Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
by: Jeong Pil Han, et al.
Published: (2021-07-01)

Evaluation of covariate effects in item response theory models
by: Gustaf J. Wellhagen, et al.
Published: (2024-05-01)

Factor VIII Level in Mothers of Patients with Severe Hemophilia A and its Impact on Joint Status
by: Iman Ragab, et al.
Published: (2023-01-01)

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A
by: Yohann Repessé, et al.
Published: (2019-08-01)

Acquired Hemophilia A with Gastrointestinal Bleeding
by: Narae Park, et al.
Published: (2020-01-01)

Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades
by: Annelies Nijdam, et al.
Published: (2015-03-01)

Bleeding Patterns among Severe Hemophilia A and B Patients in West Java
by: Muhammad Mufakkirul Islam, et al.
Published: (2020-06-01)

Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors
by: Luciana Werneck Zuccherato, et al.
Published: (2025-08-01)

Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A
by: Arne W.J.H. Dielis, et al.
Published: (2008-09-01)

Genetic Characterization of the Factor VIII Gene in a Cohort of Colombian Patients with Severe Hemophilia A with Inhibitors
by: Samuel Sarmiento Doncel, et al.
Published: (2022-05-01)

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
by: Zhen-Ping Chen, et al.
Published: (2018-01-01)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
by: Volkan Karakuş, et al.
Published: (2012-05-01)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
by: Nicholas B. Abt, et al.
Published: (2014-01-01)

Liposomal factor VIII as an efficient pharmaceutical system for the treatment of hemophilia
by: Maryam Karimi, et al.
Published: (2024-06-01)

Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
by: Kun Huang, et al.
Published: (2022-02-01)

Effect of tertiary prophylaxis with low-dose factor VIII in quality of life in adult patients with severe hemophilia A
by: Prakas Kumar Mandal, et al.
Published: (2019-01-01)

The Need for a Bleed Type–Specific Annual Bleeding Rate in Hemophilia Studies
by: Kun Huang
Published: (2024-03-01)

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity
by: Johannes Oldenburg, et al.
Published: (2015-02-01)

Benchmarking prophylaxis with factor concentrates: reference data on annualized bleeding rates in children with severe hemophilia
by: Susanna Ranta, et al.
Published: (2025-08-01)

P1663: THE EFFECTS OF OBESITY ON BLEEDING FREQUENCY AND PARAMETERS OF FIBRINOLYSIS IN PATIENTS WITH NON-SEVERE HEMOPHILIA
by: O. Königsbrügge, et al.
Published: (2022-06-01)

Bleeding phenotype in hemophilia carriers : Tunisian center experience
by: Ons Ghali, et al.
Published: (2023-01-01)

Stopping the bleed: A hemophilia B success story
by: Bhavya Krishna, et al.
Published: (2025-01-01)

Antithrombin inhibition using nanobodies to correct bleeding in hemophilia
by: Jamie M O'Sullivan, et al.
Published: (2020-03-01)

Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children
by: Nadine G. Andersson, et al.
Published: (2023-10-01)

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
by: Mark T. Reding, et al.
Published: (2024-08-01)

Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter
by: Yohann Repessé, et al.
Published: (2013-10-01)

Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor
by: Charles R. Lefèvre, et al.
Published: (2021-04-01)

Factor VIII prophylactic therapy reduces neurological complications in patients with Hemophilia A
by: José Marcelino Aragão FERNANDES, et al.

Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients
by: Séverine Henrard, et al.
Published: (2013-09-01)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
by: Runhui Wu, et al.
Published: (2021-08-01)

Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
by: Mark T. Reding, et al.
Published: (2024-12-01)

Parvovirus 4 in Individuals with Severe Hemophilia A and Matched Control Group
by: Sanaz Asiyabi, et al.
Published: (2021-07-01)

Recombinant porcine factor VIII in acquired hemophilia A: Experience from two patients and literature review
by: Alexander Hayden, et al.
Published: (2022-02-01)

Screening of Intron 1 Inversion of the Factor VIII Gene in 130 Patients with Severe Hemophilia A from a Pakistani Cohort
by: Azhar Sattar, et al.
Published: (2017-08-01)